

DATINVEST INTERNATIONAL LTD.
Suite 918, 1030 West Georgia Street
Vancouver, British Columbia
V6E 2Y3

NEWS RELEASE

DATINVEST ANNOUNCES BOARD AND MANAGEMENT OF EXXEL PHARMA

August 31 2018 – Vancouver, British Columbia – Datinvest International Ltd. (TSXV: DAI.H) (the “**Company**”) is pleased to announce that it has finalized the board of directors and management which will be appointed following completion of its proposed acquisition (the “**Business Combination**”) of Exxel Pharma Inc. (“**Exxel Pharma**”). Following completion of the Business Combination, the board of directors of the Company will be reconstituted to consist of Soren Mogelsvang, Guy Yachin, Nitin Kaushal and Nancy Retzlaff. Management of the Company will consist of Soren Mogelsvang as Chief Executive Officer, Martin Bajic as Chief Financial Officer, Daniele Piomelli as Chief Scientific Officer and Maria Wells as Corporate Secretary. The following are brief profiles of the proposed members of management and the board of directors:

Soren Mogelsvang: Director and Chief Executive Officer

Dr. Mogelsvang is the Chief Executive Officer of Exxel Pharma, and is a seasoned biotech executive and entrepreneur with over fifteen years of experience. Recently he served as President and Chief Executive Officer of Peak Pharmaceuticals, which he built from concept to a profitable veterinary health company; Co-founder and Vice-President of Research and Development at Serpin Pharma Inc., a clinical stage biotech company; Co-founder and Head of Research and Development at Caerus Discovery, an immunology company launched with support from BioWa - Kyowa Hakko Kirin and ImmunoCellular Therapeutics; Head of Cell Biology at ATCC; and Director of Laboratory and Production at Affinity BioReagents. Dr. Mogelsvang holds a PhD in Biochemistry (Cambridge, UK), and an MSc in Plant Molecular Biology (University of Copenhagen, Denmark).

Guy Yachin: Independent Director

Mr. Yachin is currently the Chief Executive Officer of Serpin Pharma, LLC, a privately held, clinical stage biotech company. Mr. Yachin is a serial entrepreneur who has led numerous biomedical companies, mostly notably he served as Chief Executive Officer of MGVS during collaborative funding with Teva Pharmaceuticals in 2009 and co-founded Chiasma Inc. which entered into a \$600 million licensing agreement with Roche in 2013. Mr. Yachin has sat on the board of multiple companies including Orgenesis, Remon Medical Technologies, Enzymotec and NanoPass. He holds a BSc. and an MBA from Technion – Israel Institute of Technology.

Nitin Kaushal: Independent Director

Mr. Kaushal is a managing director in the corporate finance practice of PricewaterhouseCoopers LLP. Mr. Kaushal has more than 25 years of experience in the financial investing, life sciences, consumer health care, health care services and medical device industries. His experience includes board of directorships with pharmaceutical and health care companies, and he has also held senior roles in investment banking, venture capital and consulting firms.

Nancy Retzlaff: Independent Director

Ms. Retzlaff is a seasoned biopharmaceutical executive with over twenty years of experience. She has held commercial leadership positions of increasing responsibility at Bayer US, Schering-Plough and Pfizer, as well as senior level positions at two start-up biopharma organizations. She brings a track record of leading successful product launches globally as well as in the United States, Europe, Japan and Canada, and has led a number of high profile brands including Cipro, Remicade, Lyrica, Aricept and Eliquis. She has broad therapeutic expertise in pain, immunology, neurosciences, infectious diseases and cardiology.

Daniele Piomelli: Chief Scientific Officer

Dr. Piomelli is an Italian-born American scientist. He studied neuroscience in New York City, with James H. Schwartz and Eric R. Kandel at Columbia University College of Physicians and Surgeons (PhD, 1983-1988) and later with Paul Greengard at the Rockefeller University (Post-doc, 1988-1990). After working at the INSERM in Paris (1990-1995) and at the Neurosciences Institute in La Jolla (1995-1998) with Nobel Laureate Gerald Edelman, he joined the University of California Irvine School of Medicine, where he is now Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry. Dr. Piomelli is the scientific cofounder of Kadmus Pharmaceuticals, Thesan Pharmaceuticals and NeoKera.

Martin Bajic: Chief Financial Officer

Mr. Bajic has over a decade of experience serving as a director, chief financial officer or consultant to numerous public companies trading on the TSX Venture Exchange or the Canadian Securities Exchange with a focus in the resource and technology industries. As a CPA, CA he will provide the Company with the requisite skills necessary for financial management and compliance with regulatory reporting requirements.

Maria Wells: Corporate Secretary

Ms. Wells has been an integral part of some of Vancouver's most successful teams in corporate finance and the venture capital markets, that have sourced, developed and facilitated capital investments which have financed and brought countless companies to market. Her professionalism and dedication to project completion have establish her as a competent and reliable partner when liaising with legal, financial and regulatory stakeholders.

About Exxel Pharma

Exxel Pharma is a privately held biopharmaceutical company, incorporated under the laws of the Province of British Columbia, focused on the development of therapeutics for the non-addictive treatment of pain, PTSD and substance addiction. The following selected financial information is taken from the audited financial statements of Exxel Pharma for the period from incorporation through to April 30, 2018, which are expected to be included in the filing statement being prepared in connection with the Business Combination:

Total Assets	\$1,121,587
Total Liabilities	\$2,747
Total Revenues	Nil
Net Loss	\$134,744

About the Business Combination

In accordance with the terms of the Business Combination, Exxel Pharma will amalgamate with a wholly-owned subsidiary of the Company, following which the resulting amalgamated entity will continue as a wholly-owned subsidiary of the Company. In consideration for completion of the Business Combination, all common shareholders of Exxel Pharma will be entitled to receive one (1) common share of the Company in exchange for every one (1) common share of Exxel Pharma that they hold. All outstanding share purchase warrants of Exxel Pharma will also be exchanged for share purchase warrants of the Company, and will be exercisable on substantially the same terms. The Company anticipates issuing 38,778,000 common shares and 6,324,000 share purchase warrants to complete the acquisition of all of the outstanding securities of Exxel Pharma.

In connection with the Business Combination, the Company intends to complete a private placement financing for proceeds of not less than \$4,000,000 (the "**Financing**"). The Financing will be conducted through the offering of subscription receipts (each, a "**Receipt**") at a price of \$0.45 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Business Combination. Upon completion of the Business Combination, each Receipt will automatically be converted into one (1) unit of the Company (each, a "**Unit**"). Each "Unit" will consist of one (1) common share of the Company and one (1) common share purchase warrant entitling the holder to acquire an additional common share at a price of \$0.90 for a period of twenty-four (24) months.

Northbay Capital Partners Corp. ("**Northbay**") is acting as financial advisor to Exxel Pharma in connection with the Business Combination. Upon the successful completion of the Business Combination, Northbay is entitled to receive a success fee equivalent to 3% of the transaction value payable in common shares. Assuming the Business Combination is completed as planned, it is expected that Northbay will be issued 1,163,340 common shares in payment of the success fee.

For further information on Exxel Pharma, readers are encouraged to review the Company's news releases of May 22nd and June 11th, and to visit: www.exxelpharma.com. Additional information on Exxel Pharma, including current financial statements, will be filed and posted on SEDAR upon the completion of a filing statement that will be prepared in connection with the Business Combination.

The Business Combination will constitute a reverse-takeover for the Company under the policies of the TSX Venture Exchange (the "**Exchange**"). Following completion of the Business Combination, it is anticipated that the Company would be listed on the Exchange as a Tier 2 Technology issuer under the name "Exxel Pharma Inc." and the ticker symbol "EXL". Closing of the Business Combination is subject to a number of conditions including completion of the Financing, receipt of all required regulatory and third party consents, including Exchange approval, and the satisfaction of other customary closing conditions. The Business Combination cannot close until the required approvals are obtained. There can be no assurance that the Business Combination will be completed as proposed or at all. Trading in the common shares of the Company will remain halted pending further filings with the Exchange.

Approval of the shareholders of the Company will not be required in connection with the Business Combination, in accordance with Exchange Policy 5.2, as the Business Combination is not a related party transaction and no other circumstances exist which may comprise the independence of the Company or other interested parties. The Company is listed on the NEX board of the Exchange, and shareholder approval is not required for any aspect of the Business Combination under applicable corporate or securities laws.

For further information, contact Emily Davis, Corporate Secretary of the Company, at 604.628.5616 or edavis@v1.ca, or Soren Mogelsvang, Chief Executive Officer of Exxel Pharma, at 720.261.1109 or soren.mogelsvang@exxelpharma.com.

On behalf of the Board,

Datinvest International Ltd.

Sean Davis, Chief Executive Officer

Completion of the Business Combination is subject to a number of conditions, including Exchange acceptance. There can be no assurance that the Business Combination will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection with the Business Combination, any information released or received with respect to the Business Combination may not be accurate or complete and should not be relied upon. Trading in the securities of the Company should be considered highly speculative.

The TSX Venture Exchange has in no way passed upon the merits of the Business Combination and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.